Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Dwight Nissley"'
Autor:
Tanmoy Bhattacharya, Thomas Brettin, James H. Doroshow, Yvonne A. Evrard, Emily J. Greenspan, Amy L. Gryshuk, Thuc T. Hoang, Carolyn B. Vea Lauzon, Dwight Nissley, Lynne Penberthy, Eric Stahlberg, Rick Stevens, Fred Streitz, Georgia Tourassi, Fangfang Xia, George Zaki
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
The application of data science in cancer research has been boosted by major advances in three primary areas: (1) Data: diversity, amount, and availability of biomedical data; (2) Advances in Artificial Intelligence (AI) and Machine Learning (ML) alg
Externí odkaz:
https://doaj.org/article/9e82654f1abd4a87a245b6b2ae1fe724
Autor:
Brian Smith, Alok K. Sharma, Roger Ma, Megan Rigby, Vandana Kumari, Dominic Esposito, Dwight Nissley, Frank McCormick, Anna E. Maciag
Publikováno v:
Molecular Cancer Research. 21:A033-A033
Up to 30% of cancers harbor activating mutations in one of three RAS genes, HRAS, NRAS, or KRAS, that drive uncontrolled cellular proliferation, alter cellular metabolism, movement, differentiation, and promote cell survival and tumor immune evasion.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::93d766b6d12f91f224bcb8e18dd43e1b
https://doi.org/10.1158/1557-3125.ras23-a033
https://doi.org/10.1158/1557-3125.ras23-a033
Autor:
Megan Rigby, John Columbus, Vanessa Wall, Dominic Esposito, Thomas Turbyville, Dhirendra Simanshu, Dwight Nissley, Frank McCormick, Anna Maciag
Publikováno v:
Molecular Cancer Research. 21:B027-B027
KRAS mutations occur in roughly 15% of cancer patients, with KRAS G12D, KRAS G12V, and KRAS G12C substitutions constituting the majority of these cases. Cancer types also display puzzling preferences for certain RAS mutations; for instance, 49% of pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::39c2bde81a8f50c933801980a3cff825
https://doi.org/10.1158/1557-3125.ras23-b027
https://doi.org/10.1158/1557-3125.ras23-b027
Autor:
Alok K. Sharma, Marcin Dyba, Dominic Esposito, Bin Wang, Pedro J. Beltran, Eli Wallace, Dwight Nissley, Frank McCormick, Anna E. Maciag
Publikováno v:
Molecular Cancer Research. 21:PR01-PR01
RAS mutations occur in approximately 20% of human cancers including the majority of pancreatic ductal adenocarcinoma (PDAC), half of colorectal cancers, and a third of all lung cancers. In cases of oncogenic activating RAS mutations, GTP hydrolysis i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0c8dd271090ccee1f0dcc2488f1ba02e
https://doi.org/10.1158/1557-3125.ras23-pr01
https://doi.org/10.1158/1557-3125.ras23-pr01